【作者】 胡毅； 冯奉仪； 林冬梅； 程书钧； 刘又宁；

【Author】 HuYi Feng Feng-Yi Lin Dong-Mei Chen Shu-Jun Liu You-Ning Department of respiratory, PLA General Hospital, Beijing 100853, CHINA

【机构】 北京市解放军总医院呼吸科； 中国医学科学院肿瘤医院；

【摘要】 目的:观察PC细胞来源的致瘤生长因子(PCDGF) 和乳腺癌耐药蛋白(BCRP)在非小细胞肺癌(NSCLC)患者病理组织切片中的表达情况,明确BCRP和PCDGF的表达与化疗疗效的关系,探讨这两种蛋白预测NSCLC化疗疗效的前景和临床应用价值。方法:对87例化疗初治晚期 NSCLC患者的肿瘤病理组织切片进行免疫组织化学染色,观察PCDGF和BCRP的表达情况,分析表达强弱与铂类为主的化疗方案治疗疗效的关系。结果:NSCLC患者化疗总有效率(OR)41．4％(36／87),其中化疗敏感者占41．4％(36／ 87),化疗抗拒者占58．6％(51／87)。PCDGF表达率为52．9％, 化疗抗拒者PCDGF表达强度(74．5％)明显高于化疗敏感者 (19．4%),(P=0．000)强阳性表达者均为化疗抗拒者,PCDGF 表达强度与化疗疗效显著相关(P=0．000),其阳性表达灵敏度为74．5％,特异度为84．8％;BCRP表达率为67．8％(59／ 87),化疗抗拒者表达强度(90．2％)明显高于化疗敏感者(36． 1％),(P=0．000)强阳性表达者均为化疗抗拒者,BCRP表达强度与化疗疗效显著相关(P=0．000),其阳性表达灵敏度为90．2％,特异度为78．0％;PCDGF和BCRP联合检测共表达特异度为92．0％。可以提高预测化疗疗效的特异性。结论: PCDGF和BCRP将可以成为应用临床免疫组织化学方法预测NSCLC一线化疗疗效的生物标记物。更多还原

【Abstract】 Obeotlve: To observe BCRP (breast cancer resistance protein) and PCDGF(PC cell-derived growth factor) expressed in the slices from paraffin-embeded tumor of NSCLC(non-smalI cell lung cancer) patients frying to investigate the relationship between the level of expression of BCRP, PCDGF proteins, and response to chemotherapy in advanced NSCLC, assessing the value of clinical application of BCRP and PCDGF detecting. Methods: Expression of PCDGF and BCRP was examined immunohistochemicaliy in slices of 87 paraffin-embeded tumor samples from chemotherapy-naive advanced NSCLC patients and Response to platinum-based chemotherapy were compared in relation to expression of each of BCRP and PCDGF. Results: The overall response rate of NSCLC patients is 41.38%(36/87), the chemosen-sitivity patients occupied 4138% (36/87) and the chemore-sistance patients 58.62% (51/87). PCDGF-positive patients occupied 52.87% in all 87 samples, the intensity of PCDGF expression in chemotherapy resistance patients (74.5%) is significantly higher than in chemotherapy sensitive patients (19.4%) (P = 0.000) and high-level expressioner all were chemotherapy-resistance patients. The intensity of PCDGF expression was significantly associated with response to chemotherapy(P = 0.000), the positive sensibility of PCDGF expression is 74.5% and specificity is 84.8%; BCRP-posi-tive patients occupied 67.82% (59/87), the intensity of BCRP expression in chemotherapy resistance patients (90.2%) is significantly higher than in chemotherapy sensitive patients (36.1%) (P = 0.000) and high-level expressioner all were chemotherapy resistance patients; The intensity of BCRP expression was significantly associated with response to chemotherapy (P = 0.000), the positive sensibility of PCDGF expression is 90.2% and specificity is 78.0%, Combined detection with PCDGF and BCRP could improve specificity(92.0%) in predicting chemo-therapeutic response. Conclusion: Positive immunostaining for BCRP and PCDGF could be a biomarker of predicting first-line chemotherapeutic response in patients with advanced NSCLC by clinical im- munohistochemical method.更多还原